Patent ID: 9051240
Filing Date: 2015-06-09
Classification: A61K,A61P,C07C,C07D

Abstract:
1. A method for treating a cognitive or psychiatric disorder, comprising the step of administering to a patient in need thereof an effective amount of a compound of formula (I): wherein: X is —O—; Y is hydrogen, —OH or —O(C Z is ═O or ═S; R is —(C R group where R R R R its pharmaceutically acceptable salts and the isolated optical isomers or mixtures of optical isomers of the compound and their pharmaceutically acceptable salts, wherein (a) said cognitive disorder is selected from the group consisting of Mild Cognitive Impairment (MCI) and cognitive disorders associated with autism, dyslexia, attention deficit hyperactivity disorder, schizophrenia, obsessive compulsive disorder, psychosis, bipolar disorder, depression, Tourette's syndrome, disorder of learning in children, adolescents and adults, Age Associated Memory Impairment, Age Associated Cognitive Decline, Alzheimer's Disease, Parkinson's Disease, Down's Syndrome, traumatic brain injury, Huntington's Disease, Progressive Supranuclear Palsy (PSP), HIV, stroke, vascular diseases, Pick's or Creutzfeldt-Jacob disease, multiple sclerosis (MS), and drug-induced cognitive worsening, and (b) said psychiatric disorder is selected from the group consisting of major depression, apathy, dysthymia, mania, bipolar disorder, bipolar disorder type I, bipolar disorder type II, cyclothymic disorder, rapid cycling, ultradian cycling, hypomania, schizophrenia, schizophreniform disorder, schizoaffective disorder, personality disorder, attention disorders with or without hyperactive behavior, delusional disorder, brief psychotic disorder, shared psychotic disorder, substance-induced psychotic disorder, anxiety disorder, generalised anxiety disorder, panic disorder, post-traumatic stress disorder, impulse control disorder, phobic disorder, smoke and drug addiction and alcoholism.